Study results presented at ASCO-GI reinforce value of Genomic Health's Oncotype DX Co

[News]

Genomic Health, Inc. today announced presentation of three studies at the American Society of Clinical Oncology Gastrointestinal Cancer Symposium, including one finding that high tumor grade was not a marker of higher recurrence risk in stage II colon cancer, suggesting that other markers, such as the Oncotype DX® Recurrence Score® (RS) test as well as T-stage and mismatch repair (MMR) status, should be considered by physicians during the treatment decision-making process.

More... (http://www.news-medical.net/news/20110125/Study-results-presented-at-ASCO-GI-reinforce-value-of-Genomic-Healths-Oncotype-DX-Colon-Cancer-test.aspx)